[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"HiDO Technologies\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":78},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,52],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":51},"100660013","homecare-medication-management-for-people-with-dementia-100660013",false,"NCT07872072","HomeCare Medication Management for People With Dementia","Behavioral Shifts in Dementia Patients Using Novel Pharmacy Home Robotics: A Cost-Effective Approach to Aging in Place","Inclusion Criteria:\n\n* Age 65 years or older.\n* Living with dementia, Alzheimer's Disease, or Alzheimer's Disease Related Dementias (AD\u002FADRD) according to standardized diagnostic criteria.\n* Capable of providing informed consent or have a legally authorized representative available to consent on their behalf.\n* Access to a smartphone, tablet, or computer with internet connectivity. Able to communicate in either English or Spanish.\n\nExclusion Criteria:\n\n* Significant comorbidities or medical conditions that could interfere with participation or severe cognitive function.\n* History of severe psychiatric illness or substance abuse disorder.\n* Recent participation in other clinical trials targeting cognition or dementia.\n* Unwillingness or inability to comply with study procedures.\n* Residence in a long-term care facility or institutional setting that may limit access to the home-based study intervention.","ALL","65 Years",{"count":19,"type":20},120,"ESTIMATED","INTERVENTIONAL",[23],"NA","This study will evaluate whether the HomeCare medication management system can improve medication adherence and related outcomes for adults age 65 and older living with dementia, Alzheimer's disease, or related dementias.\n\nHomeCare is an internet-connected medication management device that can automate medication dispensing, monitor medication use, and provide alerts to caregivers. The system is integrated with a Pharmacy Distribution System designed to track medications from pharmacy delivery through use in the home.\n\nA total of 120 participants with dementia will be randomly assigned to one of two groups. One group will use the HomeCare system, while the other group will continue using standard medication management methods, such as pill bottles or blister packs. Participants will be followed for 12 months. The main outcome is medication adherence. The study will also examine hospitalizations and emergency room visits, cognitive function, caregiver burden, quality of life, satisfaction, and changes in medication-management behavior. Caregivers will also participate in surveys and study assessments. The study is intended to determine whether HomeCare can improve medication management and support both people living with dementia and their caregivers.",[26,27],"Dementia","Alzheimer's Disease and Related Dementias",[29,30,31,32,33,34,35,36,37,38],"Medication Adherence","HomeCare","Medication Management","Pharmacy Distribution System","Caregiver Burden","Cognitive Function","Hospitalization","Quality of Life","Video Direct Observed Therapy","Older Adults","NOT_YET_RECRUITING","2026-10-07",{"date":42,"type":43},"2026-10-13","ACTUAL",{"date":45,"type":20},"2027-01-01",{"date":47,"type":20},"2027-05-31",{"name":49,"class":50},"HiDO Technologies","INDUSTRY",1,{"id":53,"slug":54,"hasResults":11,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":4,"eligibilityCriteria":58,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":59,"targetDuration":4,"studyType":21,"phases":61,"briefSummary":62,"conditions":63,"keywords":64,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":51},"100640333","preventing-medication-mismanagement-in-people-living-with-dementia-100640333","NCT07600684","Preventing Medication Mismanagement in People Living With Dementia","Preventing Medication Mismanagement in People Living With Dementia Through Automated Medication Dispensing With Facial Recognition and Video Observation","Inclusion Criteria:\n\n* Participants must have a diagnosis of dementia.\n* They must be prescribed one medication indicated for dementia symptoms such as Aricept, Namenda, or Donepezil, and be prescribed at least one additional medication.\n* Participants must have an active study partner that is willing to be enrolled into the study and willing to receive messages and alerts from the HiDO-ALZ system if medications are missed. The study partner must also agree to complete surveys about the participant's ongoing health.\n* Participants must be willing to allow research staff to enter their homes to install the HiDO-ALZ device and to complete study activities.\n\nThe participant's medications will be reviewed by the UCD pharmacist prior to randomization. If a participant has contraindicated medication(s), this medication will need to be removed or justified by the prescribing clinician prior to randomization. The research team and HiDO staff will work with the UCD pharmacist and prescribing clinician to resolve contraindicated medications prior to randomization. If a resolution is not possible, the participant will not be enrolled.\n\n•MoCA score of 15 to 22 or previous MMSE score of 21 to 26 within the last 6 months.\n\nIf no test is available, the participants will be given a MoCA test after signing consent to confirm eligibility.\n\nExclusion Criteria\n\n* The inability to demonstrate capacity to consent or assent as determined by the Capacity Assessment Checklist.\n* Individuals who do not have a study partner\u002Fcaregiver (e.g., spouse, adult child) to complete questionnaires.\n* Participants with MoCA scores below 15 will be excluded as they may not be able to use the device independently.\n* Participants who are unable or unwilling to complete the cognitive testing or unwilling to complete the blood tests.",{"count":60,"type":20},50,[23],"The purpose of this research is to learn whether the HiDO-ALZ device can improve medication compliance and health outcomes in participants with dementia that need to take daily medication.",[26],[65,66,67,68],"dementia","cognitive impairment","self-medicating device","compliance","RECRUITING","2026-05-18",{"date":72,"type":43},"2026-05-22",{"date":74,"type":43},"2026-05-05",{"date":76,"type":20},"2027-12-31",{"name":49,"class":50},""]